Ultrasonographic ovarian mass scoring system for predicting malignancy in pregnant women with ovarian mass

Se Jin Lee, MD¹, Hye Rim Oh, MD², Sunghun Na, MD, PhD¹, Han Sung Hwang, MD, PhD³, Seung Mi Lee, MD, PhD²

¹Department of Obstetrics and Gynecology, Kangwon National University Hospital, School of Medicine, Kangwon National University, Chuncheon; ²Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul; ³Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea

During routine antenatal ultrasound examinations, an ovarian mass can be found incidentally. In clinical practice, the differential diagnosis between benign and malignant ovarian masses is essential for planning further management. Ultrasound imaging has become the most popular diagnostic tool during pregnancy, with the recent development of ultrasonography. In non-pregnant women, several methods have been used to predict malignant ovarian masses before surgery. The International Ovarian Tumor Analysis (IOTA) group reported several scoring systems, such as the IOTA simple rules, IOTA logistic regression models, and IOTA assessment of different NEOplasias in the adneXa. Other researchers have also evaluated the malignancy of ovarian masses before surgery using scoring systems such as the Sassone score, pelvic mass score, DePriest score, Lerner score, and Ovarian-Adnexal Reporting and Data System. These researchers suggested specific features of ovarian masses that can be used for differential diagnosis, including size, proportion of solid tissue, papillary projections, inner wall structure, locules, wall thickness, septa, echogenicity, acoustic shadows, and presence of ascites. Although these factors can also be measured in pregnant women using ultrasound, only a few studies have applied ovarian scoring systems in pregnant women. In this article, we reviewed various scoring systems for predicting malignant tumors of the ovary and determined whether they can be applied to pregnant women.

Keywords: Ovarian cysts; Ovarian cancer; Diagnostic imaging; Ultrasoundography; Pregnant women

Introduction

Malignant ovarian tumors are the seventh most common malignancy in women worldwide, accounting for 3.7% of all female cancer cases. These tumors have a high mortality rate owing to late detection, with 67% of the patients already having progressive disease at the time of diagnosis [1]. A recent study reported that ovarian tumors are found in 2% to 10% of pregnant women [2-4]. Most ovarian tumors detected during pregnancy are reported to disappear in late pregnancy, and those less than 5 cm are reported to disappear at a rate of 71% to 89% [3,5,6]. Nevertheless, clinicians should still consider the possibility of malignant ovarian tumors to ensure proper management.

Although there have been no definite ultrasound-based diagnostic criteria for ovarian cancer, many efforts have been
made to distinguish benign from malignant tumors using ultrasonographic findings. Various ovarian scoring systems have been proposed for non-pregnant gynecological patients. With recent advances in ultrasonography, some studies have reported the detailed features of tissue composition using shades of colors and attempted to diagnose the histological and clinical stages of ovarian cancer before surgery [7-9].

Ultrasonography is the most commonly used tool for evaluating ovarian tumors during pregnancy because of its relative safety. As other diagnostic modalities, such as computed tomography (CT) or magnetic resonance angiography with contrast, cannot be used during pregnancy, the application of an ovarian scoring system based on the findings of ultrasonography, which can be safely performed during pregnancy, may help determine the timing of surgery during or after pregnancy.

In this article, we reviewed several scoring systems for predicting malignant ovarian tumors and discussed the applicability of the scoring systems during pregnancy.

Review of ovarian mass scoring systems

1. International Ovarian Tumor Analysis (IOTA)

The IOTA study is the largest study on the accuracy of ultrasound for the diagnosis of ovarian tumors, which has brought many benefits to the field of transvaginal ultrasonography (TVS). Studies have been conducted to explain the morphological and Doppler ultrasound characteristics of these tumors [10,11].

The IOTA group was started 15 years ago to create an appropriate “evidence-based” algorithm for all types of ovarian tumors. IOTA includes several scoring systems, including the IOTA simple rules, IOTA logistic regression (LR) models, and IOTA assessment of different NEOplasias in the adnexa (ADNEX) model.

The first scoring system is the IOTA simple rules. This is based on a set of five ultrasound features indicative of a benign tumor (B-features) and five ultrasound features indicative of a malignant tumor (M-features). If only B-features are observed, the ovarian tumor is classified as benign. If the ovarian tumor shows only M-features, it is classified as malignant. However, this scoring system has a disadvantage when both B- and M-features or features that do not correspond to these criteria are observed [12].

The simple rules system was reported to have a sensitivity of 93% and a specificity of 90% [13]. Thereafter, several validation papers reported a sensitivity of 86% to 93% and a specificity of 88% to 94%. However, when classifying inconclusive cases as malignant, the sensitivity was 91% to 96% and the specificity was 65% to 87% [10].

In 2005, more universally useful LR models, IOTA LR1 and LR2, were developed to distinguish between malignant and benign adnexal tumors before surgery [14]. The IOTA LR1 is calculated using a total of 12 factors according to the following criteria: (1) history of ovarian cancer (yes=1, no=0), (2) current hormonal treatment (yes=1, no=0), (3) patient’s age (in years), (4) maximum diameter of the ovarian mass (in millimeters), (5) presence of pain during the examination (yes=1, no=0), (6) presence of ascites (yes=1, no=0), (7) presence of blood flow within a solid papillary projection (yes=1, no=0), (8) presence of a completely solid tumor (yes=1, no=0), (9) maximal diameter of the solid component (but with no increase >50 mm), (10) irregular internal cyst walls (yes=1, no=0), (11) presence of acoustic shadows (yes=1, no=0), and (12) color score (1, 2, 3, or 4). The formula is \( y = \frac{1}{1+e^{-z}} \), where \( z = -6.7468 + 1.5985 \times 1(1) - 0.9983 \times 2(2) + 0.0326 \times 3(3) + 0.00841 \times 4(4) - 0.8577 \times 5(5) + 1.1737 \times 6(6) + 1.1737 \times 7(7) + 0.0496 \times 8(8) + 0.0496 \times 9(9) + 1.1421 \times 10(10) - 2.3550 \times 11(11) + 0.4916 \times 12(12) \) and \( e \) is the mathematical constant and base value of natural logarithms [14].

The IOTA LR2 is calculated based on six of the above criteria: (3), (6), (7), (9), (10), and (11). The formula used to determine the probability of malignancy is as follows: \( y = \frac{1}{1+e^{-z}} \), where \( z = -5.3718 + 0.0354 \times 3(3) + 1.6159 \times 6(6) + 1.1768 \times 7(7) + 0.0697 \times 9(9) + 0.9586 \times 10(10) - 2.9486 \times 11(11) \). As with LR1, the probability \( y \) is dichotomized at a score of 0.1 to make a predictive diagnosis of cancer [14,15]. In the original article, the area under the receiver operating characteristic curve (AUROC) of LR1 was 0.936, the sensitivity was 92.7%, and the specificity was 74.3%. The AUROC of LR2 was 0.916, the sensitivity was 89.9%, and the specificity was 70.7%. Thereafter, in several subsequently published validation papers, when the LR2 cutoff value was 10%, the sensitivity was 88% to 95% and the specificity was approximately 80% to 90% [10].

The IOTA ADNEX is the first risk model to differentiate between benign and four types of malignant ovarian tumors ( borderline, stage I cancer, stage II-IV cancer, and secondary...
metastatic cancers). The ADNEX model includes three clinical factors and six ultrasound factors. The clinical factors include age (years), serum CA125 level (U/mL), and type of the center where the patient underwent ultrasound. The six predictors in the ADNEX model are ultrasound variables, as follows: maximal diameter of the lesion (mm), percentage of solid tissue (%), number of papillary projections (0, 1, 2, 3, and >3), presence of more than 10 cyst locules (yes/no), acoustic shadows (yes/no), and presence of ascites (yes/no) [16]. In the original article, the AUC of the ADNEX model was 0.954 (95% confidence interval, 0.947 to 0.961) for the development data and 0.943 (0.934 to 0.952) for the validation data [16]. Using a previously proposed cutoff of 10% [14], the sensitivity for malignancy was 96.5% and the specificity was 71.3% for the validation data. The model well discriminated between benign tumors and each of four types of malignancy, with AUCs between 0.85 (benign versus borderline) and 0.99 (benign versus stage II-IV cancer) [16].

Table 1-1 summarizes the details of each IOTA scoring system.

2. Sassone score
The Sassone score was developed by Sassone et al. [17]. This scoring system evaluates four parameters: inner wall structure, wall thickness, septum, and echogenicity [17]. First, the inner wall structure is divided into four categories: smooth or irregularities (≤3 mm), papillarities (>3 mm), and not applicable (mostly solid), with scores of 1, 2, 3, and 4, respectively. Second, the wall thickness refers to points 1, 2, and 3 in three categories: thin (≤3 mm), thick (>3 mm), and not applicable (mostly solid). Third, the septa are classified into three categories: none, thin (≤3 mm), and thick (>3 mm) with scores of 1, 2, and 3, respectively. Fourth, echogenicity is divided into five categories: sonolucent, low echogenicity, low echogenicity with echogenic core, mixed echogenicity, and high echogenicity, which refer to points 1, 2, 3, 4, and 5, respectively (Table 1-2). The maximum Sassone score is 15, and the minimum score is 4. In this scoring system, the cutoff score is 9. In the original article, the sensitivity and specificity were 100% and 83%, respectively [17].

3. Pelvic mass score (PMS)
PMS is a scoring system proposed by Rossi et al. [8], which includes the sonomorphological index-Sassone score, logarithmetic value of CA125 level, type of vascularity, menopausal status, and resistive index of the adnexal mass. The formula for the PMS was proposed as follows:

### Table 1-1. Ovarian mass scoring system: IOTA

| Scoring system | Score |
|----------------|-------|
| **IOTA simple rules** | |
| Benign tumor (B-features) | Malignant tumor (M-features) |
| B1: Unilocular | M1: Irregular solid tumor |
| B2: Presence of solid components where the largest solid component has a largest diameter <7 mm | M2: Presence of ascites |
| B3: Presence of acoustic shadows | M3: At least four papillary structures |
| B4: Smooth multicystic tumor with largest diameter <100 mm | M4: Irregular multicystic solid tumor with largest diameter ≥100 mm |
| B5: No blood flow (color score 1) | M5: Very strong blood flow (color score 4) |
| **IOTA LR**<sup>a</sup> | y=[1/(1+exp<sup>-z</sup>]), where z=-6.7468+1.5985 (1)-0.9983 (2)+0.0326 (3)+0.00841 (4)-0.8577 (5)+1.5513 (6)+1.1737 (7)+0.9281 (8)+0.0496 (9)+1.421 (10)-2.3550 (11)+0.4916 (12) |
| **IOTA LR**<sup>b</sup> | y=[1/(1+exp<sup>-z</sup>)], where z=-5.3718+0.0354 (3)+1.6159 (6)+1.1768 (7)+0.0697 (9)+0.9586 (10)-2.9486 (11) |
| **IOTA ADNEX** | They used IOTA ADNEXA calculator. The factors are follows; age of the patient at examination, oncology center, maximal diameter of the lesion, maximal diameter of the largest solid part, more than 10 locules, number of papillations acoustic shadows present, ascites present, and serum CA125 or without serum CA125. |

IOTA, International Ovarian Tumor Analysis; LR, logistic regression; ADNEX, assessment of different NEoplasias in the adneXa.

<sup>a</sup>LR factor: (1) personal history of ovarian cancer (yes=1, no=0), (2) current hormonal therapy (yes=1, no=0), (3) age of the patient (in years), (4) maximum diameter of the lesion (in millimeters), (5) the presence of pain during the examination (yes=1, no=0), (6) the presence of ascites (yes=1, no=0), (7) the presence of blood flow within a solid papillary projection (yes=1, no=0), (8) the presence of a purely solid tumor (yes=1, no=0), (9) maximal diameter of the solid component (expressed in millimeters, but with no increase >50 mm), (10) irregular internal cyst walls (yes=1, no=0), (11) the presence of acoustic shadows (yes=1, no=0), and (12) the color score (1, 2, 3, or 4).
PMS = \frac{[SASS \times \log(CA125) \times VAS \times MS]}{RI}

In this formula, SASS is the numeric value of the Sassone score, log(CA125) is the base 10 logarithm of the CA125 level, VAS is the type of vascularization (peripheral=1, central/septal=2), MS is the menopausal state (pre-menopausal=1, post-menopausal=2), and RI is the numeric value of the resistance index of the pelvic mass (Table 1-2). The ROC curve method recommended a cutoff value of 29 for PMS analysis. The sensitivity of PMS was reported to be 93%, and the specificity was approximately 88% [8].

4. DePriest score
DePriest et al. [18] proposed a morphology index based on sonographic findings of ovarian cancer. It included the ovarian volume, wall structure, and septal structure. Scores of 0 to 4 were developed for each category according to specific criteria. First, ovarian volume was divided into five categories: $<10 \text{ cm}^3$, $10-50 \text{ cm}^3$, $>50-200 \text{ cm}^3$, $>200-500 \text{ cm}^3$, and $>500 \text{ cm}^3$. The inclusion of the ovarian volume was considered important. DePriest et al. [18] also noted that no malignant ovarian tumor had a volume of $<10 \text{ cm}^3$. In another study, no malignancies were observed in postmenopausal women Table 1-2. Ovarian mass scoring system: SASS and PMS

| Scoring system | Score |
|----------------|-------|
| **SASS**       |       |
| Inner wall structure (mm) | Score 1: smooth | Score 2: irregularities ≤3 | Score 3: papillarities >3 | Score 4: not applicable, mostly solid | - |
| Wall thickness (mm) | Score 1: thin (<3) | Score 2: thick (>3) | Score 3: not applicable, mostly solid | - | - |
| Septa (mm) | Score 1: none | Score 2: thin (<3) | Score 3: thick (>3) | - | - |
| Echogenicity | Score 1: sonolucent | Score 2: low echogenicity | Score 3: low echogenicity with echogenic core | Score 4: mixed echogenicity | Score 5: high echogenicity |
| **PMS** | PMS = \frac{[SASS \times \log(CA125) \times VAS \times MS]}{RI} |

SASS, Sassone score; PMS, pelvic mass score; log(CA125), 10 logarithm of the CA125 levels; VAS, type of vascularization (peripheral=1; central/septal=2); MS, menopausal state (pre-menopausal=1; post-menopausal=2); RI, numeric value of the resistance index of the pelvic mass.

Table 1-3. Ovarian mass scoring system: DePriest score and Lerner score

| Scoring system | Score |
|----------------|-------|
| **DePriest score** |       |
| Volume | 0 $<10 \text{ cm}^3$ | 1 10-50 cm$^3$ | 2 $>50-200 \text{ cm}^3$ | 3 $>200-500 \text{ cm}^3$ | 4 $>500 \text{ cm}^3$ |
| Cyst wall structure | Smooth (<3 mm thickness) | Smooth (≥3 mm thickness) | Papillary projection (<3 mm) | Papillary projection (≥3 mm) | Predominantly solid |
| Septa structure | No septa | Thin septa (<3 mm) | Thick septa (3 mm to 1 cm) | Solid area (≥1 cm) | Predominantly solid |

| **Lerner score** |       |
| Wall structure (mm) | Smooth or small irregularities <3 | - | Solid or not applicable | Papillarities ≥3 |
| Shadowing | Yes | No | - | - |
| Septa (mm) | None or thin (<3) | Thick (≥3) | - | - |
| Echogenicity | Sonolucent or low-level echo or echogenic core | - | - | Mixed or high |
with unilocular ovarian cysts <3 cm in diameter. Second, the wall structure was characterized as follows: smooth (<3 mm thickness), smooth (≥3 mm thickness), papillary projection (<3 mm), papillary projection (≥3 mm), and predominantly solid. They noted that the most consistent sonographic characteristic of malignant ovarian tumors was abnormality of the wall structure. In their study, all malignant ovarian tumors had a papillary projection or solid component protruding from the inner wall of the tumor. Third, the septal structure was divided into five categories: no septa, thin septa (<3 mm), thick septa (3 mm to 1 cm), solid area (≥1 cm), and predominantly solid (Table 1-3). Papers published after the study by DePriest et al. [18] proved that the shape of the septa is an important component of malignancy evaluation [19]. In the original article, the cutoff value of the scoring system was 5. The sensitivity of the DePriest score was 100%, and the specificity was approximately 61.2% [19].

5. Lerner score

In 1993, the Lerner score was developed. It included four parameters: wall structure, shadowing, septa, and echogenicity. The modified scoring system proposed by Lerner et al. [20] was primarily based on the Sassone scoring system [17]. The score assignments previously used in the Sassone scoring system were changed according to the results of a computer-based multiple linear regression analysis, and two other modifications were included. The computer-based analysis included a category in which the variable wall thickness was discarded as insignificant and described as a “shadow,” defined as the acoustic echo loss behind the sound-absorbing structure. This new category, “shadowing,” allows for a more accurate identification of benign cystic teratoma, which was the cause of many false-positive results in previous studies.

Scores of 0 to 3 were developed for each category according to specific criteria. First, the wall structure was divided into three categories: smooth or small irregularities <3 mm (0 points), solid or non-applicable (2 points), and papillary irregularities ≥3 mm (3 points). Second, the shadowing score consisted of “yes” (0 points) and “no” (1 point) categories. Third, the septa were divided into two categories: none or thin (0 points) and thick (1 point). Fourth, echogenicity was also divided into two categories: sonolucent or low-level echo or echo-genic core (0 points) and mixed or high (3 points) (Table 1-3). In the original article, the cutoff value of the scoring system was 3. The sensitivity and specificity of the Lerner score were 96.8% and 77%, respectively [20].

6. Ovarian-Adnexal Reporting and Data System (O-RADS)

In 2018, the American College of Radiology divided ovarian and adnexal tumors into six categories to construct a unified imaging report for communication and quality improvement. The six categories were as follows: 1) description of major categories, physiological category or not; 2) description of size; 3) description of solid lesions; 4) description of cystic lesions; 5) description of vascularity; and 6) general and extra-ovarian findings. First, the major categories were divided into two categories: physiological category (follicle and corpus luteum) and lesion category (unilocular, unilocular cyst with solid component, multilocular cyst without solid elements, multilocular cyst with solid component, and solid or solid appearance). Second, size was defined as the maximum diameter. Third, solid lesions were divided into two categories: external contour (smooth and irregular) and internal content (acoustic shadowing). Fourth, cystic lesions included the inner margin (papillary projection or nodule, and smooth/irregular) and internal content (anechoic fluid and hyperechoic components). Fifth, vascularity was divided into four color scores (CS): 1 (no flow), 2 (minimal flow), 3 (moderate flow), and 4 (very strong flow). Sixth, the general and extra-ovarian findings were as follows: cul-de-sec fluid, ascites, and peritoneal thickening or nodules.

With reference to these descriptions, risk classification was performed for tumors and six O-RADS scores were created. The meaning of each score was as follows: O-RADS 0, incomplete evaluation; O-RADS 1, physiological category (normal premenopausal ovary); O-RADS 2, almost certainly benign category (1% risk of malignancy) [21] (including simple cysts, unilocular cysts with smooth walls, and ovarian mass with maximal size less than 10 cm); O-RADS 3, lesions with a low risk of malignancy (1% to 10%) (including unilocular cysts [≥10 cm], typical dermoid cysts, endometriomas, and hemorrhagic cysts [≥10 cm]; unilocular cysts of any size with an irregular inner wall [<3 mm height]; multilocular cysts [<10 cm]; cysts with a smooth inner wall and CS=1-3; and solid smooth mass of any size with CS=1); O-RADS 4, lesions with an intermediate risk of malignancy (10% to 50%) (including multilocular cysts without a solid component, unilocular cysts with a solid component, multilocular cysts with a solid com-
ponent, and solid tumors); O-RADS 5, lesions with a high risk of malignancy (>50%) (including unilocular cysts of any size, with ≥4 papillary projections and CS=any; multilocular cysts of any size with a solid component and CS=3-4; solid smooth mass of any size with CS=4; solid irregular mass of any size with CS=any; and ascites or peritoneal nodules).

In the validation study of O-RADS, the optimal cutoff value for predicting malignancy was O-RADS >3. The sensitivity of O-RADS was 98.7%, and the specificity of this system was 83.2% [22]. Table 1-4 summarizes the details of O-RADS.

### Previous studies on ovarian masses in pregnant women

Several authors have reported that 51% to 92% of adnexal masses resolve during pregnancy [6,22,23], and the predictors of sustainability are mass size greater than 5 cm and a “complex” structure on TVS [24]. The incidence of acute complications is known to be less than 2% [25]. The American College of Obstetrics and Gynecologists has published guidelines outlining methods for the diagnosis and manage-

### Table 1-4. Ovarian mass scoring system: ORADS

| O-RADS 0 | O-RADS 1 | O-RADS 2 | O-RADS 3 | O-RADS 4 | O-RADS 5 |
|---------|---------|---------|---------|---------|---------|
| Definition | Incomplete evaluation | The physiologic category (normal premenopausal ovary) | The almost certainly benign category (1% risk of malignancy) | Lesions with low risk of malignancy (1% to 10%) | Lesions with intermediate risk of malignancy (10% to 50%) | Lesions with high risk of malignancy (>50%) |
| Characteristic | - | - | Simple cysts, Unilocular cysts with smooth walls, and maximal size of ovarian mass is less than 10 cm | Unilocular cyst (≥10 cm), typical dermoid cysts, endometriomas, and hemorrhagic cysts (≥10 cm); unilocular cyst, any size with irregular inner wall (<3 mm height); multilocular cyst (<10 cm); Smooth inner wall, CS=1-3; any size solid smooth mass with CS=1 | Multilocular cyst without solid component, Unilocular cyst with solid component, multilocular cyst with solid component, and solid | Unilocular cyst, any size, ≥4 papillary projection, CS=any, any size multilocular cyst with solid component, CS=3-4, any size solid smooth with CS=4, any size solid irregular mass with CS=any; ascites and/or peritoneal nodules |

O-RADS, Ovarian-Adnexal Reporting and Data System.

### Table 2. Previous studies on ultrasound imaging of ovarian tumors during pregnancy

| Study | Study population | Type of studies | Objective | Conclusion |
|-------|-----------------|----------------|-----------|------------|
| Platek et al. [28] (1995) | 31 | Retrospective study (in USA, Bronx Municipal Hospital Center and the Weiler Hospital of the Albert Einstein College of Medicine) | To evaluate the pathological features and outcomes of pregnancies complicated by persistent adnexal masses managed conservatively or surgically | - Ovarian cancer in pregnancy is rare, but the frequency of ovarian cysts diagnosed in pregnancy is much higher - Complications of abdominal surgery may be increased in pregnancy |
| Bromley and Benacerraf [29] (1997) | 125 | Retrospective study (single hospital in USA, Massachusetts General Hospital) | To determine the accuracy of ultrasound diagnosis and perinatal results in pregnant women with ovarian mass | - Prenatal sonography can accurately characterize maternal adnexal lesions - Sonographic appearance; simple cyst, dermoid appearance, complex cyst, septate cyst etc. |
Table 2. Continued

| Study                        | Study population | Type of studies | Objective                                                                                                                                                                                                 | Conclusion                                                                                                                                                                                                 |
|------------------------------|------------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Bernhard et al. [6] (1999)   | 422              | Retrospective study (single hospital in USA, Washington University Medical Center) | To determine factors predicting the persistence of sonographically identified adnexal masses in pregnancy                                                                                               | • Most adnexal masses were small, simple cysts that did not pose a risk to the pregnancy  
• Even most large-scale or ultrasonically complex ovarian masses have spontaneously disappeared  
• The best predictors of persistent ovarian mass were ultrasound shape and size  |
| Schmeler et al. [31] (2005)  | 59               | Retrospective study (single hospital in USA, Women & Infants’ Hospital of Rhode Island, Brown University Medical School) | To determine whether there is a risk of adverse maternal and fetal outcomes when surgery is delayed in pregnant women with ovarian mass                                                                            | • Close observation of antenatal surgery in pregnant women with ovarian mass is a reasonable alternative  
• Evaluated for mass size, presence/absence of septae, echogenicity, wall thickness, papillary projections, border characteristics, and vascularity |
| Czekierdowski et al. [26] (2021) | 36              | Retrospective multicenter study (two departments of obstetrics and gynecology, one department of obstetrics and pathological pregnancy, and one gynecological oncology center in Poland) | To evaluate the accuracy of preoperative diagnosis of ovarian mass in pregnant women in SA, the IOTA group SRR and ADNEX models                                                                              | Subjective assessment is the best predictive method for complex adnexal masses found on prenatal ultrasonography in pregnant women. For inexperienced sonographers, the SRR and ADNEX scoring systems can also be used for the characterization of these tumors, but the serum tumor markers CA125 and HE4 and the ROMA algorithms appear less accurate |
| Lee et al. [27] (2021)       | 236              | Retrospective multicenter study (eleven referral hospitals in South Korea) | To compare ultrasonographic ovarian mass scoring systems (IOTA, Sassone, and Lerner) and evaluate which factors can help predict the malignancy risk in pregnant women                                                | • Among the ultrasound characteristics, six factors showed statistically significant differences (maximal diameter of ovarian mass, maximal diameter of ovarian solid mass, inner wall structure, wall thickness, thickness of septation, and papillarity)  
• The combined model was developed with these six components  
• Malignant ovarian tumors can be predicted with high accuracy using either the Sassone scoring system or a combined model in pregnant women |
| Usui et al. [45] (2000)      | 69               | Retrospective study (single hospital in Japan) | To assess the impact on patients who underwent prenatal surgery and fetal outcomes                                                                                                                      | • Ovarian mass may be associated with adverse fetal outcomes  
• Surgical interventions less than 24 weeks of gestation may not themselves have been associated with adverse outcomes |
| Masclinì et al. [46] (2017)  | 34               | Retrospective observational study (four ultrasound centers in Italy) | To elucidate the ultrasound features that can discriminate between benign and malignant ovarian cysts with papillary projections but no other solid component in pregnant women                                      | • Ground-glass echogenicity and papillations with a smooth contour on ultrasound are most likely to be decidualized endometriomas  
• Cysts with anechoic or low-level echogenicity and papillations with an irregular contour suggest borderline malignancy |

SA, subjective assessment; IOTA, International Ovarian Tumor Analysis; SRR, simple rules risk; ADNEX, assessment of different NEoplasias in the adnexa; HE4, human epididymis protein 4; ROMA, Risk of Ovarian Malignancy Algorithm.
ment of adnexal masses that occur outside of pregnancy [25]. However, clinical guidelines for women with ovarian masses during pregnancy remain elusive.

Previous studies evaluated only a few ultrasound functions during pregnancy, and most studies focused on outcomes in the presence of an ovarian mass (Table 2).

Bernhard et al. [6] investigated the risk factors for persistent ovarian masses during pregnancy in the largest study on ovarian masses during pregnancy. They divided ovarian masses into four sonographic categories: simple cysts with an average diameter of <5 cm measured on ultrasound, simple cysts with an average diameter of ≥5 cm, polycysts (mass containing one or more simple cysts), and complex masses. A cyst with smooth walls and no internal echoes was defined as a simple cyst. Masses that did not meet the criteria for hard masses or simple cysts were defined as complex masses. All simple cysts with an average diameter of >1 cm, all polycystic masses, and all complex masses of any size were included in the analysis. Most ovarian masses identified on ultrasound during pregnancy were small simple cysts that did not pose a pregnancy risk. Most large or ultrasonically complex masses spontaneously resolved. In this study, the factors that best predicted the persistence of an ovarian mass were shape and size on ultrasound [6].

The most recent study (published in 2021) evaluated the accuracy of malignancy prediction between ovarian scoring systems and subjective assessment [26]. It was a retrospective multicenter study conducted in Poland. The authors concluded that subjective evaluation is the best predictor of complex adnexal masses found on antenatal ultrasonography in pregnant women. For inexperienced sonographers, the IOTA simple rules risk and ADNEX scoring systems can also be used for the characterization of these tumors; however, the serum tumor markers CA125 and human epididymis protein 4 (HE4) and the Risk of Ovarian Malignancy Algorithm (ROMA) algorithms seem less accurate [26].

In the Sassone scoring system, high echogenicity had the highest score, and the larger the solid portion, the higher the probability of malignancy. The DePriest and Lerner scores also increased as the size of the solid portion increased. In the Lerner score, high scores were assigned to mixed or high echogenicity and papillarity in the wall structure. In addition, only the IOTA ADNEX and PMS included CA125 level. In the analysis using the Lerner scoring system, it was also found that papillary masses within the inner wall structure category had a greater percentage of malignancy than masses that were mostly solid. For this reason, papillary masses were assigned a higher weight. Significant values were obtained in the regression analysis using these four variables, and regression coefficients were used to calculate the final weight of each variable [20].

2. Ovarian mass scoring systems in pregnant women

In pregnant women, the incidence of adnexal masses is ap-
approximately 0.05% to 3.2% \[6,23\]. Mature teratomas and para-ovarian or luteal cysts are the most commonly reported pathological diagnoses \[28-30\]. Approximately 1.2% to 6.8% of pregnant women with persistent malignant masses are

| Table 3. Factors included in each scoring system |
|------------------------------------------------|
| **Scoring system** | **Factor** | **Tumor marker** |
|---------------------|------------|------------------|
| IOTA simple rules   | - Locule   | -                |
|                     | - Locule   |                  |
|                     | - Proportion of solid tissue (%) |    |
|                     | - Acoustic shadows (yes/no) |    |
|                     | - Irregularity |            |
|                     | - Number of papillary projections |   |
|                     | - Blood flow (color score) |    |
|                     | - Presence of ascites (yes/no) |   |
| IOTA LR             | - Personal history of ovarian cancer (yes=1, no=0) |   |
|                     | - Current hormonal therapy (yes =1, no=0) |   |
|                     | - Age of the patient (in years) |          |
|                     | - Maximum diameter of the lesion (in mm) |          |
|                     | - Presence of pain during the examination (yes=1, no=0) | |
|                     | - Presence of ascites (yes=1, no=0) |    |
|                     | - Presence of blood flow within a solid papillary projection (yes=1, no=0) |   |
|                     | - Presence of a purely solid tumor (yes=1, no=0) |   |
|                     | - Maximal diameter of the solid component (expressed in millimeters, but with no increase >50 mm) |   |
|                     | - Irregular internal cyst walls (yes=1, no=0) |   |
|                     | - Presence of acoustic shadows (yes=1, no=0) |   |
|                     | - Color score (1, 2, 3, or 4) |          |
| IOTA ADNEX          | - Age of the patient at examination | CA125 |
|                     | - In oncology center |          |
|                     | - Maximal diameter of the lesion (mm) |          |
|                     | - Proportion of solid tissue (%) |          |
|                     | - Number of papillary projections (0, 1, 2, 3, >3) |          |
|                     | - Presence of more than 10 cyst locules (yes/no) |          |
|                     | - Acoustic shadows (yes/no) |          |
|                     | - Presence of ascites (yes/no) |          |
| Sassone             | - Inner wall structure | - |
|                     | - Wall thickness | |
|                     | - Septa | |
|                     | - Echogenicity | |
| PMS                 | - Sassone score | CA125 |
|                     | - Type of vascularization (peripheral=1; central/septal=2) | |
|                     | - Numeric value of the resistance index of the pelvic mass | |
| DePriest            | - Volume | - |
|                     | - Cystic wall structure | |
|                     | - Septa structure | |
| Lerner              | - Wall structure | - |
|                     | - Shadowing | |
|                     | - Septa | |
|                     | - Echogenicity | |
| O-RADS              | - Major category (locule, solid elements) | - |
|                     | - Size | |
|                     | - Solid or solid-appearing lesions (irregularity, acoustic shadowing) | |
|                     | - Cystic lesions (papillarity, irregularity) | |

IOTA, International Ovarian Tumor Analysis; LR, logistic regression; ADNEX, assessment of different NEoplasias in the adneXa; PMS, pelvic mass score; O-RADS, Ovarian-Adnexal Reporting and Data System.
diagnosed with malignancy [23,31-33].

Most ovarian masses are discovered incidentally during routine ultrasound examinations in pregnant women [4,34-36]. Previously, the detection rate of such masses was low because of the lack of techniques for early detection [34]. However, the incidence and detection rate of ovarian masses significantly increased with the application of ultrasonography in antenatal care [4,34,37].

With the developments in ultrasound technology, many studies have been conducted on scoring systems for malignancy evaluation using ultrasound characteristics in non-pregnant women; however, no scoring system has been applied to pregnant women.

When making clinical decisions in pregnant women with ovarian masses, both the mother and the fetus should be considered, which makes the clinical decision more complex. Pregnancy complications and malignancy are the most important factors in the decision making process.

If the ovarian scoring systems mentioned above are applied to pregnant women, the following should be noted: first, as the gestational weeks increase, ascites become difficult to detect with ultrasound in pregnant women because they are hidden in the uterus. Second, the diagnostic utility of serum tumor markers in women with ovarian masses found during pregnancy remains controversial. The CA125 level is elevated during pregnancy. It peaks in the first trimester (range, 7.251 units/mL) and steadily decreases thereafter [38]. It is similar between pregnant women in the second and third trimesters and control women [39]. In general, slight elevations in CA125 level during pregnancy are not associated with malignancy [24]. CA125 and another widely used tumor marker, HE4, have been analyzed in pregnant women; however, the prognostic value of these markers alone or in combination with the ROMA is unknown in pregnancy [40-42].

Ultrasound is helpful in evaluating pregnant women with ovarian masses. Various ultrasound features of ovarian masses of various etiologies can be evaluated in pregnant women in actual clinical practice. Some ultrasound features may raise the suspicion of malignancy, including but not limited to the presence of solid components, increased wall thickness, multi-location large tumors with a maximum diameter of >6 cm, and total internal septum >2-3 mm. The presence of papillary protrusions, increased vascularity during Doppler examination, and ascites can also be clues to suspect malignancy [37,43,44].

Other imaging tests, such as CT, are inappropriate for assessing ovarian masses during pregnancy because of fetal radiation effects. Pelvic ultrasonography is considered the modality of choice for evaluating ovarian masses found during pregnancy and is suitable for guiding surgical intervention, if necessary [34,43]. Ultrasound may also be used to monitor changes in the ovarian mass as the gestational age progresses. It is also important to monitor the progression or regression of ovarian masses, such as in terms of size and characteristics [34].

Conclusion

In this review, we investigated the usefulness of existing ovarian scoring systems in pregnant women with ovarian masses. Unlike for general gynecological patients, the available imaging modalities for pregnant women are limited. Ultrasonography can be the optimal tool considering that pregnant women undergo ultrasound examinations several times during prenatal care. However, few research results have been published on whether the prediction of malignancy using ovarian scoring systems in pregnant women is accurate. Hence, more studies are needed on the application of scoring systems for the evaluation of ovarian mass malignancy in pregnant women.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Ethical approval

This study does not require approval of the Institutional Review Board because no patient data is contained in this article.

Patient consent

Not applicable.
www.ogscience.org

Funding information

None.

Acknowledgments

We are grateful to the patients included in this study. We thank the medical staff for their assistance.

References

1. Mohaghegh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics 2012;32:1751-73.
2. Goh WA, Rincon M, Bohrer J, Tolosa JE, Sohaey R, Riaño R, et al. Persistent ovarian masses and pregnancy outcomes. J Matern Fetal Neonatal Med 2013;26:1090-3.
3. Condous G, Khalid A, Okaro E, Bourne T. Should we be examining the ovaries in pregnancy? Prevalence and natural history of adnexal pathology detected at first-trimester sonography. Ultrasound Obstet Gynecol 2004;24:62-6.
4. Glanc P, Salem S, Farine D. Adnexal masses in the pregnant patient: a diagnostic and management challenge. Ultrasound Q 2008;24:225-40.
5. Hogston P, Lilford RJ. Ultrasound study of ovarian cysts in pregnancy: prevalence and significance. Br J Obstet Gynaecol 1986;93:625-8.
6. Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstet Gynecol 1999;93:585-9.
7. Araujo KG, Jales RM, Pereira PN, Yoshida A, de Angelo Andrade L, Sarian LO, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. Ultrasound Obstet Gynecol 2017;49:778-83.
8. Rossi A, Braghin C, Soldano F, Isola M, Capodicasa V, Londero AP, et al. A proposal for a new scoring system to evaluate pelvic masses: pelvic masses score (PMS). Eur J Obstet Gynecol Reprod Biol 2011;157:84-8.
9. Al-Musalhi K, Al-Kindi M, Ramadhan F, Al-Rawahi T, Al-Hatali K, Mula-Abed WA. Validity of cancer antigen-125 (CA-125) and risk of malignancy index (RMI) in the diagnosis of ovarian cancer. Oman Med J 2015;30:428-34.
10. Kaijser J. Towards an evidence-based approach for diagnosis and management of adnexal masses: findings of the International Ovarian Tumour Analysis (IOTA) studies. Facts Views Vis Obgyn 2015;7:42-59.
11. Campbell S. Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. Ultrasound Obstet Gynecol 2012;40:245-54.
12. Timmerman D, Van Calster B, Testa A, Savelli L, Fischero da, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumour Analysis group. Am J Obstet Gynecol 2016;214:424-37.
13. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008;31:681-90.
14. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. J Clin Oncol 2005;23:8794-801.
15. Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting. Ultrasound Obstet Gynecol 2018;51:829-35.
16. Van Calster B, Van Hoorde K, Froyman W, Kaijser J, Wynants L, Landolfo C, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts Views Vis Obgyn 2015;7:32-41.
17. Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 1991;78:70-6.
18. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51:7-11.
19. El Sokkary HHAH. The efficacy of ultrasonographic mor-
phological index using Depriest score in ovarian cancer prediction. Int J Reprod Contracept Obstet Gynecol 2016;5:4200-5.

20. Lerner JP, Timor-Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol 1994;170(1 Pt 1):81-5.

21. Andreotti RF, Timmerman D, Strachowski LM, Froyman W, Benacerraf BR, Bennett GL, et al. O-RADS US risk stratification and management system: a consensus guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 2020;294:168-85.

22. Cao L, Wei M, Liu Y, Fu J, Zhang H, Huang J, et al. Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): analysis on 1054 adnexal masses. Gynecol Oncol 2021;162:107-12.

23. Wanetta G, Mariani E, Lissoni A, Ceruti P, Trio D, Strobelt N, et al. A prospective study of the role of ultrasound in the management of adnexal masses in pregnancy. BJOG 2003;110:578-83.

24. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Practice bulletin No. 174: evaluation and management of adnexal masses. Obstet Gynecol 2016;128:e210-26.

25. Whitecar MP, Turner S, Higby MK. Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management. Am J Obstet Gynecol 1999;181:19-24.

26. Czekierdowski A, Stachowski N, Smoleń A, Kluz T, Łoziński T, Mitruski A, et al. Sonographic assessment of complex ultrasound morphology adnexal tumors in pregnant women with the use of IOTA simple rules risk and ADNEX scoring systems. Diagnostics (Basel) 2021;11:414.

27. Lee SJ, Kim YH, Lee MY, Ko HS, Oh SY, Seol HJ, et al. Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women. Gynecol Oncol 2021;163:385-91.

28. Platek DN, Henderson CE, Goldberg GL. The management of a persistent adnexal mass in pregnancy. Am J Obstet Gynecol 1995;173:1236-40.

29. Bromley B, Benacerraf B. Adnexal masses during pregnancy: accuracy of sonographic diagnosis and outcome. J Ultrasound Med 1997;16:447-52; quiz 453-4.

30. Sunoo CS, Terada KY, Kamemoto LE, Hale RW. Adnexal masses in pregnancy: occurrence by ethnic group. Obstet Gynecol 1990;75:38-40.

31. Schmeler KM, Mayo-Smith WW, Peipert JF, Wetinez S, Manuel MD, Gordinier ME. Adnexal masses in pregnancy: surgery compared with observation. Obstet Gynecol 2005;105(5 Pt 1):1098-103.

32. Surampudi K, Nirmalan PK, Gundabattula SR, Chandran JB. Management of adnexal masses in pregnancy: our experience from a tertiary referral perinatal centre in South India. Arch Gynecol Obstet 2015;291:53-8.

33. Balci O, Gezginc K, Karatayli R, Acar A, Celik C, Colakoglu MC. Management and outcomes of adnexal masses during pregnancy: a 6-year experience. J Obstet Gynecol Res 2008;34:524-8.

34. YacoboZZi M, Nguyen D, Rakita D. Adnexal masses in pregnancy. Semin Ultrasound CT MR 2012;33:55-64.

35. Leiserowitz GS. Managing ovarian masses during pregnancy. Obstet Gynecol Surv 2011;66:479-102.

36. Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med 1998;43:387-92.

37. Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med 2012;10:86.

38. Wang Z, Zhou F, Xiao X, Ying C. Serum levels of human epididymis protein 4 are more stable than cancer antigen 125 in early and mid-term pregnancy. J Obstet Gynaecol Res 2018;44:2053-8.

39. Gasiorowska E, Kluz T, Lipski D, Warchol W, Tyskarski A, Nowak-Markwitz E. Human epididymis protein 4 (HE4) reference limits in Polish population of healthy women, pregnant women, and women with benign ovarian tumors. Dis Markers 2019;2019:3890906.

40. Uslu B, Dogan S, Özdem S, Simşek T. Serum concentrations of HE4 and Ca125 in uncomplicated pregnancies: a longitudinal study. J Obstet Gynaecol Res 2020;40:70-6.

41. Aggarwal P, Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol
44. Grigoriadis C, Eleftheriades M, Panoskaltsis T, Bacanu AM, Vitoratos N, Kondi-Pafiti A, et al. Ovarian cancer diagnosed during pregnancy: clinicopathological characteristics and management. G Chir 2014;35:69-72.
45. Usui R, Minakami H, Kosuge S, Iwasaki R, Ohwada M, Sato I. A retrospective survey of clinical, pathologic, and prognostic features of adnexal masses operated on during pregnancy. J Obstet Gynaecol Res 2000;26:89-93.
46. Mascilini F, Savelli L, Scifo MC, Exacoustos C, Timor-Tritsch IE, De Blasis I, et al. Ovarian masses with papillary projections diagnosed and removed during pregnancy: ultrasound features and histological diagnosis. Ultrasound Obstet Gynecol 2017;50:116-23.